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Heart failure has become a worldwide epidemic of the 21st century with increasing impact on healthcare systems. The 2012 ESC and 2013 ACCF/
AHA guidelines have set the stage forcurrent therapy to reduce mortality and morbidity. There is a dawnof hope for therapyof acute and diastolic
heart failure; it has become clearer that patients benefit from mitral reconstruction and which patients benefit from heart failure management
programmes; genetics and proteomics advance in great strides; competing concepts of cell therapy seem to spiral, hopefully upwards; and we
can further nurture our hope for evidence-based individualized diagnostic and therapy.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords Heart failure
Introduction
Heart failure has become a worldwide epidemic of the 21st century
with increasing impact on healthcare systems. The 2012 ESC and
2013 ACCF/AHA guidelines have set the stage for current therapy
to reduce mortality and morbidity.1,2 The guidelines are valid and
based on study evidence for therapy of chronic systolic left heart
failure of patients without comorbidities (Figure 1). They admit that
evidence is sparse for diagnostics, acute heart failure, co-morbidities,
heart failure with preserved ejection fraction (HFpEF), many surgical
procedures, and end-of-life care. In addition, it can be questioned
whether the same therapy fits to any aetiology and genetic back-
ground of individual patients. Adding further principles of neurohu-
moral inhibition did not further improve therapy. Thus, many
questions are left by the ESC-guideline2012 andACC/AHA guideline
2013 to be answered by research in 2013 and in the future.
Heart failure diagnostics, evidence
of no evidence
While conventional echocardiography remains the bread-and-butter
technique, the value of speckle tracking has recently been proposed
for estimating prognosis and as a clue in differential diagnosis.3 Mag-
netic resonance imaging may detect and localize fibrosis and subtle
changes of circumferential strain in an asymptomatic population4 as
prognostic indicators of heart failure admission and mortality. Ana-
lysis of biomarkers or specific features in imaging may contribute to
better understanding of mechanisms and have the potential to indi-
vidualize prevention and therapy. So far, the consequences remain
unclear of such studies for therapy.
Controlled endpoint studies for diagnostics are missing in patients
with heart failure. In addition, heart failure therapy requires informa-
tion on an aetiology and potential complications, in other words, it is
compulsory to combine all clinical information, relevant laboratory
tests, and imaging for diagnostics. Thus, diagnostic tools need to be
evaluated in the context of diagnostic algorithms rather than in pro-
tocols insensitive to information obtained by complementary or
competing methods. These studies are virtually missing and guide-
lines remain on the level of expert recommendations.1,2
Acute heart failure, a dawn of hope
for therapy?
Acutely decompensatedheart failurehas recently been recognizedas
an entity which severely burdens prognosis. The challenge combat-
ting acute heart failure has generated a number of trials with classic
as well as innovative drugs such as levosimendan, nesiritide, rolofyl-
line, tezosentan, andomecamtivmecarbil: so far in vain.Only recently,
a dawn of hope has come up with the peptide relaxin-2, which regu-
lates circulation and renal perfusion in pregnancy. Serelaxin, the re-
combinant human relaxin-2, reduced a dyspnoea score which was
a primary endpoint, and 180-day mortality which was a tertiary end-
point.5 A clue for the success of this study may have been the exclu-
sion of hypotensive patients. This and other principles are currently
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being followed up including studies with mortality as a primary
endpoint.
Heart failure in real life: managing
co-morbidities
‘The systemic disease “heart failure” starts before clinical manifest-
ation’.6 This may be due to the underlying disease which may be sys-
temic like atherosclerosis, to multiple organ complications of heart
failure, or the omnipresence of comorbidities. The Meta-analysis
Global Group in Chronic Heart Failure has reported on almost
40 000 patients with chronic heart failure. Next to age, male
gender, ejection fraction, New York Heart Association class, renal
failure, diabetes, and chronic obstructive pulmonary disease were
confirmed as comorbid predictors of mortality.7 The EHJ column
‘The heart and other organs’ discussed interactions of the heart
with the gut, liver, kidney, and the bronchopulmonary system. Cogni-
tion deficiency and depression severely burden on morbidity and
mortality. The diversity of multimorbidity and consequent polyphar-
macy is incompatible with the reductive concept of clinical studies
and requires a more comprehensive approach. Recent guidelines
consider this inconsistency but do not offer solutions. At least they
suggest management programmes for selected patients. Results of
controlled studies on such programmes have been controversial
but after all it seems that nurse-and-doctor-based programmes
may be extremely effective in advanced heart failure.8 Telemetry
may supplement these programmes. At least patients with implanted
devices seem to have benefits from telemonitoring technology
(In Time Study ESC Highlights 2013). Less ill patients get by with
the management of their general practitioner.9
Heart failure with preserved
ejection fraction, a surrogate for
comorbidity?
For years, clinical studies on HFpEF have been most frustrating. The
concepts for treating heart failurewith reduced ejection fraction gen-
erally have failed in large HFpEF trials. Prevalence of HFpEF seems to
rise in our aging society and patients appear to become more and
more multimorbid. Two latest studies may exemplify the
problem.10,11 The aldosterone antagonist spironolactone showed
some benefit on left ventricular diastolic function in the Aldo-DHF
study but did not reduce the combined cardiovascular primary
outcome in the TOPCAT trial (late breaking session at AHA 2013).
The RELAX study, testing the effect of the phosphodiesterase-5 in-
hibitor sildenafil, was completely negative. In the RELAX trial, 43%
had diabetes mellitus, 19% COPD, 51% atrial fibrillation or flutter,
and 35% anaemia. In the Aldo-DHF study, comorbidities were
present but prevalence was somewhat lower (diabetes: 17%,
COPD: 3%, a trial fibrillation: 5%, average Hb: 13.8 g/dL). Neverthe-
less, comorbidities may dominate the course of heart failure and may
thus defeat potential benefit of a cardiovascular approach of therapy.
Figure 1 Patients may develop heart failure on the basis of various cardiovascular risk factors and heart diseases. Numerous comorbidities and
complications add up to the high complexity of heart failure. Gaps in evidence of the ESC-guideline 2012 include diagnostics, acute heart failure,
co-morbidities, diastolic heart failure, many surgical procedures, individualized therapy, and end-of-life care.
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In this clinical syndrome, physical exercise couldbeanattractivealter-
native to drugs since it may have beneficial effects on HFpEF as well as
on various comorbidities.
Individualized medicine
Daily life medicine needs to individualize heart failure therapy consid-
ering specific patient requirements and requests including but also
beyond evidence offered by guidelines. There have been strong con-
cepts deriving an individualized approach from pathophysiologic con-
siderations. One example may be cardiac resynchronization therapy
(CRT) which has proved to be beneficial for patients even in mild
heart failure but with wide bundle branch block and asynchronous
left ventricular contraction. Pressure from various sides is high to
widen the indication to a more general population who does not
meet the criteria which have been the conceptual basis for this
therapy. It needed a large trial to show that patients with systolic
heart failure and a QRS duration of ,130 ms had no benefit from
CRT.12 This negative trial was of particular value since it answered
a clinically most relevant question but also proved the pathophysio-
logic concept which confines CRT.
Personalized medicine may substantially add to this approach if it
includes all available information. Genome-wide association studies
(GWAS) and plasma proteomics may identify potential new biomar-
kers for hypertrophy, and chronic or acutely decompensated heart
failure. Variants of genes involved in free radical generation, dysregu-
lation of iron homeostasis, and accumulation of cardiotoxicanthracy-
clines may predict anthracycline-induced cardiotoxicity.13 However,
the combination of genetic and clinical information performs super-
ior. This may impact on the indication for early heart failure therapy
and/or on a potential future specific preventive therapy perhaps with
a smallmolecule that selectivelybinds toTOP2B.14 Genome-wideas-
sociation studies may identify novel risk loci and genetic predispos-
ition for cardiac disease. Thus, GWAS may put forward hypotheses
for mechanisms which may be substantiated by functional studies
and then give rise to new therapies. Obviously, genetics may be
most valuable in rare and monogenetic disease. But cardiac hyper-
trophy and failure are regulated on transcriptional, translational,
and post-translational levels.15 The majority of our patients need to
relyon our capability to adjust guidelines to their individual condition.
Surgical procedures
Heart failure surgery has become a rapidly evolving field.
Mechanical-assist technology develops so fast that most studies
finish up with an outdated device. Most spectacular progress has
been made in valve surgery. Mitral valve reconstruction is clearly su-
perior to artificial valves. The MitralRegurgitation International Data-
base has shown in 1021 patients that early mitral reconstruction
compared with initial medical therapy reduced mortality and the
risk of heart failure.16 In ischaemic mitral regurgitation, valve repair
and replacement revealed similar end-systolic volumes at 12 months
but in the repair group recurrenceofmoderate-to-severemitral regur-
gitation was high (32.6% vs. 2.3%, in replacement).17 Valve surgery has
got strong competition by interventional procedures with potential
impact on heart failure; this will be discussed elsewhere in this journals
issue. In contrast, surgical left ventricular reconstruction still awaits the
definition of the subgroup of heart failure patients which may profit
fromtheprocedure.18 Hastyconclusions fromtheSTICH-trial that via-
bility testing is not needed may hamper further in depth research.
Results of the STICH-trial may have been different if viability testing
had been used in all patients for triage to preselected procedures.
Studies are urgently required which predefine meticulously patients
by testing for ischaemia and viability. Individualized therapy is probably
most important for surgical decisions.
New principles in therapy
Despite successof standard heart failure therapy,morbidityand mor-
tality remain unacceptably high. Adding angiotensin receptor block-
ers (ARBs) or the renin inhibitor aliskiren to standard angiotensin
converting enzyme inhibitors (ACEIs) has not added benefit but
increased side effects.19 These studies suggest that the principle of
inhibiting the renin-angiotensin system has reached its limits. It
remains unclear whether aliskiren instead of an ARB or ACEI would
have been superior to the older drugs or that the combination
could be effective in certain subgroups like patients without diabetes
mellitus. The ethical consideration that standard therapy may not be
withheld from our study patients and that new drugs have to be
tested on top of standard therapy creates a difficult situation for clin-
ical research. Angiotensin converting enzyme inhibitors have been
tested against previously available vasodilators, and ARB’s against
ACEI. We probably have to bring the dogma in question since
drugs may be better instead of, but not on top of standard therapy.
This is considered in the ongoing ATMOSPHERE20 trial which
includes an arm testing aliskiren vs. enalapril.
We also have to think about reducing the number of pills and prin-
ciples considering the polypharmacy faced by our multimorbid heart
failure patients. It seems that we are well on the way to lose one prin-
ciple. Studies have suggested no benefit but rather increased mortal-
ity among patients taking digoxin even in the presence of a trial
fibrillation. But digitalis has been declared dead many times and
further retrospective analyses or registries add only weak evidence
to weak evidence. Anyway, there are strong rationales for the need
of new concepts in drug therapy rather than for new drugs in estab-
lished concepts. Of those which have reached the clinical study level,
intravenous ferric carboxymaltose may represent such a new
concept. The independence of its effects from anaemia suggests
indeed newand so far unknownmechanisms of action. Neutral endo-
peptidase (neprylisin) inhibition or novel soluble guanylatecyclase sti-
mulators like riociguat may be other semi-new concepts. Other new
concepts are promising but have not yet made it to clinical testing.
Gene therapy may address receptors or receptor-kinase expression
so far not approachable by conventional drugs. Therapy with or
against microRNA is another principle awaiting clinical evaluation.21
Finally, there are major efforts ongoing to establish cell therapy.
Shock wave-facilitated intracoronary administration of bone
marrow cells22 or endogenous cardiac stem cells23 may contribute
to improved cardiac function.
Conclusions
Numerous questions in heart failure research are left by the year
2013 to be answered by research in 2014. Many evidence blanks in
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the actual guidelines have still remained but we have got closer to fill
some of them. There is some hope for therapy of acute and diastolic
heart failure. Progress in cardiac surgery and valve interventions still
await prove of their relevance for the course of heart failure. It has
become clearer which patients benefit from heart failure management
programmes.Competingconceptsof cell therapyseemtospiral, hope-
fully upwards; genetics and proteomics are still a long way off heart
failure management but we can further nurture our hope for evidence-
based individualized diagnostics and therapy. All these advances will
further add to the complexity of heart failure management, and re-
search will require more and more interdisciplinarity.
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